Mass Tort Lead Pricing: What Docket Tier, Diagnosis Threshold, and SOL Window Do to Your Cost Per Case
They switched to us. Lead price went up — $550 per lead on Roundup and AFFF. Their cost per signed retainer dropped to $2,100.
They paid 57% more per lead. Their cost per case fell 72%.
That gap — $5,300 per signed retainer — on 20 cases a month is $1,272,000 in annual CPR savings. From the same intake team. The same states. The same dockets.
The only variable was whether the leads were actually qualified before delivery.
This is the pricing conversation most firms are not having. They compare per-lead prices across vendors, pick the cheaper one, and wonder why the economics never close. Lead price is not the number. Cost per signed retainer is the number. And the two move in opposite directions when qualification is real.
Here’s how mass tort lead pricing actually works — and what each variable does to your cost per case.
Why Mass Tort Leads Cost More Than MVA Leads
Mass tort leads run $450–$600+ per lead. MVA leads run $250–$450. The gap exists for three compounding reasons. Miss any one of them and you’ll keep making the same purchasing mistake.
Reason 1: The plaintiff pool is smaller.
An MVA funnel targets anyone who had a car accident and meets basic qualifying criteria. That’s a large, geographically distributed population that generates volume at scale.
A Roundup funnel targets people who used Roundup brand glyphosate herbicide for two or more years and have been diagnosed with non-Hodgkin’s lymphoma. That’s a fundamentally smaller population. A Depo-Provera funnel targets women who received injectable Depo-Provera specifically — not oral progesterone, not other contraceptives — for at least a year, and who have a meningioma brain tumor diagnosis.
Smaller plaintiff populations mean higher cost per qualified submission. The economics of the ad campaign are more expensive per conversion because the eligible audience is narrower. That generation cost passes through to the lead price.
Reason 2: The qualification depth is higher.
A properly built mass tort pre-screen confirms product by exact brand name, exposure duration and dates, docket-specific qualifying diagnosis, SOL under the discovery rule, and representation status. That’s five gates versus the two or three gates on a standard MVA form.
More gates mean more disqualification. More disqualification means fewer leads delivered per thousand visitors. Fewer delivered leads per thousand visitors means higher cost per delivered lead. This is not vendor markup — it’s the arithmetic of docket-specific qualification.
A vendor offering mass tort leads at $200 per lead is either not doing docket-specific qualification or running a shared model. The price tells you which.
Reason 3: The case values justify it.
A standard MVA soft-tissue case settles in the $15,000–$75,000 range. At 33% contingency, that’s $5,000–$25,000 in attorney fees. A firm paying $2,000 per signed retainer on a $5,000 fee case is at 40% acquisition cost. The math gets thin fast.
A qualifying Roundup case — documented NHL, multi-year glyphosate exposure — settles for $100,000–$500,000+. At 33% contingency: $33,000–$165,000 in attorney fees. A firm paying $3,000 per signed retainer on a $100,000 fee case is at 3% acquisition cost.
The case value is what makes the lead price rational. Higher diagnosis thresholds and lower volume mean higher generation costs — but the settlement economics absorb them without breaking the ROI model.
The Three Variables That Actually Drive Mass Tort Lead Pricing
There is no single price for mass tort leads. There is a price per docket, modified by three variables. Every vendor quote you receive should be explainable by these three factors. If a vendor can’t explain their pricing in these terms, they don’t understand what they’re selling.
Not all active dockets are equal in generation cost or case value. The market has settled into rough tiers:
| Tier | Dockets | Price Range |
|---|---|---|
| Tier 1 — High value, mature MDL | Mesothelioma, AFFF, Roundup | $550–$650+ |
| Tier 2 — Active MDL, growing demand | Depo-Provera, NEC Formula, Hair Relaxer, Hernia Mesh, PFAS | $475–$550 |
| Tier 3 — Emerging or maturing | Ozempic, Social Media, Tepezza, Suboxone | $450–$500 |
| Tier 4 — Late-stage or winding down | Camp Lejeune (tightening), Zantac, 3M Earplugs | Declining |
Tier 4 pricing signals buyer demand is exiting. If you’re paying Tier 1 prices on a Tier 4 docket, ask why.
Tier 1 — High case value, mature MDL: Mesothelioma, AFFF, Roundup. These are dockets with established bellwether trial outcomes, known settlement ranges, and active buyer demand from firms that have been in the MDL long enough to know exactly what a qualifying plaintiff is worth. Generation costs are highest because the plaintiff populations are well-defined and the qualifying criteria are strict. Prices run $550–$650+ per lead.
Tier 2 — Active MDL, growing buyer demand: Depo-Provera, NEC Formula, Hair Relaxer, Hernia Mesh, PFAS. These are dockets past initial certification but still building toward peak acquisition activity. Buyer demand is strong and growing. Generation costs are moderate because the plaintiff pools are larger than Tier 1. Prices run $475–$550 per lead.
Tier 3 — Emerging or maturing dockets: Ozempic, Social Media, Tepezza, Suboxone. Either early in the MDL cycle with settlement value still being established, or maturing with the plaintiff class increasingly aggregated. Prices run $450–$500 per lead.
Tier 4 — Late-stage or winding down: Camp Lejeune post-filing deadline tightening, Zantac after major dismissals, 3M Earplugs as the MDL concludes. Acquisition economics become unfavorable. Prices drop as buyer demand exits. If you’re still paying Tier 1 prices on a Tier 4 docket, the vendor is selling you yesterday’s market.
Within the same docket, the diagnosis threshold determines the price.
AFFF leads confirming any PFAS-related diagnosis are cheaper to generate but produce lower case values and higher intake disqualification. AFFF leads confirming specifically bladder cancer, kidney cancer, or testicular cancer with documented FMCSA exposure history cost more to generate — fewer people meet the criteria — but produce substantially higher case values and near-zero disqualification at intake.
The diagnosis threshold is the single most controllable quality variable in mass tort pricing. A firm that accepts any AFFF diagnosis will pay less per lead and dramatically more per signed retainer. A firm that requires a specific qualifying cancer with documented exposure history will pay more per lead and substantially less per retainer.
This is not a binary choice. Most dockets allow threshold calibration — you tell the vendor which diagnosis qualifications are acceptable, and the funnel screens accordingly. Tighter thresholds mean fewer leads and higher per-lead cost. They also mean lower intake burden and higher close rates. The optimal threshold is wherever the CPR math closes best for your firm’s specific intake capacity and docket economics.
A qualifying plaintiff with 900 days remaining on their SOL window is worth more than an otherwise identical plaintiff with 90 days remaining. The firm has more time to develop the case, gather medical records, and negotiate from a position of strength.
Vendors who verify SOL under the docket-specific framework — including the discovery rule — will charge more for leads because the verification infrastructure costs more to build and operate. Vendors who apply generic PI SOL logic will deliver leads with no SOL guarantee. You’ll discover the problem at intake — after you’ve paid.
Ask any vendor: “How do you verify SOL on mass tort leads, and what framework are you applying?” If the answer is “we confirm the incident was within the statute of limitations” — they’re using PI logic. That’s wrong. The answer should name the specific discovery rule application and the docket’s federal filing deadline.
The Real Number: Cost Per Signed Retainer by Docket
Per-lead price tells you what the invoice says. Cost per signed retainer tells you whether the economics work.
Here’s how the math closes across active dockets at current pricing and realistic close rates:
| Docket | Lead Price | Close Rate | CPR | Avg Case Fee | Acq Cost % |
|---|---|---|---|---|---|
| Mesothelioma | $600+ | 15–18% | $3,333–$4,000 | $264,000 | 1.3–1.5% |
| AFFF | $575 | 16–19% | $3,026–$3,594 | $82,500 | 3.7–4.4% |
| Roundup | $550 | 16–20% | $2,750–$3,438 | $49,500 | 5.6–6.9% |
| Depo-Provera | $500 | 15–19% | $2,632–$3,333 | $66,000 | 4.0–5.0% |
| NEC Formula | $500 | 14–18% | $2,778–$3,571 | $99,000 | 2.8–3.6% |
Ozempic not included — settlement range still establishing from bellwether outcomes.
In every Tier 1 and Tier 2 docket, the acquisition cost as a percentage of expected attorney fees runs under 7%. The only scenario where mass tort lead pricing breaks the economics is when the leads aren’t docket-specific — when intake disqualification runs 40-50% and the effective CPR doubles.
What Generic Mass Tort Pricing Actually Costs You
The $350 lead looks cheaper than the $550 lead. Here’s what it actually costs.
A vendor offering mass tort leads at $350 is either running one funnel for all dockets, running a shared model, or skipping meaningful diagnosis verification. All three produce the same outcome: high intake disqualification.
The price on the invoice and the price you actually pay per case are two different numbers. The only one that determines whether mass tort lead buying makes money is the second one.
Frequently Asked Questions
The firms overpaying on mass tort leads are almost never overpaying on the per-lead invoice. They’re overpaying at intake — in staff hours, disqualification overhead, and close rates that never reach what docket-specific leads would produce.
Fix the qualification. The price per lead takes care of itself.
$2,100 CPR. Not $7,400.
Docket-specific qualification. OTP-verified. Full compliance documentation. The lead price goes up. The cost per case goes down.